View in EDS

941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)

Saved in:
Bibliographic Details
Title: 941TiP A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Authors: Khalique, S.1 (AUTHOR), Oliva, M.2 (AUTHOR), Even, C.3 (AUTHOR), Dziadziuszko, R.4 (AUTHOR), Dietz, A.5 (AUTHOR), Italiano, A.6 (AUTHOR), Melichar, B.7 (AUTHOR), Martinez-Galan, J.8 (AUTHOR), Brydøy, M.9 (AUTHOR), Thouvenin, J.10 (AUTHOR), Rutkowski, T.11 (AUTHOR), Hitre, E.12 (AUTHOR), Guix Arnau, M.13 (AUTHOR), Lopez Criado, M.P.14 (AUTHOR), Jürgens, T.15 (AUTHOR), Bratland, Å.16 (AUTHOR)
Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS653-S653. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2024.08.1002